This multicentre trial recruited 1704 overweight patients with T2DM to investigate whether there is any advantage between conventional group and intensive glucose control with metformin, chlorpropamide, glibenclamide and insulin, respectively.10 The gene discussed is INS; the disease is type 2 diabetes mellitus.